Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aripiprazole - VS Pharmatech

Next Previous
Drug Profile

Aripiprazole - VS Pharmatech

Alternative Names: VS-101 - VS Pharmatech

Latest Information Update: 22 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VS PharmTech
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Dopamine D2 receptor partial agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Head and neck cancer

Most Recent Events

  • 22 May 2025 VS PharmTech plans a phase II trial for Squamous cell cancer (Combination therapy), in May 2025 (NCT06959082)
  • 13 Jan 2023 Chemical structure information added
  • 01 Sep 2022 Phase-I clinical trials in Head and neck cancer (Adjunctive treatment) in South Korea (PO) (KCT0007606)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top